J. Safra Sarasin Holding AG Buys New Holdings in Cencora, Inc. (NYSE:COR)

J. Safra Sarasin Holding AG bought a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 18,499 shares of the company's stock, valued at approximately $4,156,000.

Several other institutional investors and hedge funds also recently bought and sold shares of COR. JFS Wealth Advisors LLC lifted its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Cencora in the fourth quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC lifted its position in shares of Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after acquiring an additional 69 shares in the last quarter. Kentucky Trust Co purchased a new position in shares of Cencora in the fourth quarter valued at about $33,000. Finally, WASHINGTON TRUST Co lifted its position in shares of Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Cencora

In related news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total value of $4,108,507.99. Following the completion of the sale, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,223 shares of company stock worth $13,580,967 over the last three months. 10.80% of the stock is owned by corporate insiders.

Cencora Trading Up 1.3 %

Shares of NYSE:COR traded up $3.66 on Friday, hitting $286.05. 1,815,757 shares of the company's stock were exchanged, compared to its average volume of 1,522,859. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $296.65. The stock has a market capitalization of $55.47 billion, a price-to-earnings ratio of 40.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The business's 50 day simple moving average is $268.09 and its two-hundred day simple moving average is $249.54. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.77%. Cencora's payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Finally, Morgan Stanley set a $288.00 price objective on Cencora in a research report on Tuesday, April 15th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $284.55.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.